029 Group SE

M&A Activity • Dec 18, 2002

News Details

Ad-hoc | 18 December 2002 07:42

Rhein Biotech N.V. english

Rhein Biotech enters into vaccine plant contract in Vietnam Ad-hoc-announcement transmitted by DGAP. The issuer is solely responsible for the content of this announcement. ——————————————————————————– Rhein Biotech enters into vaccine plant contract in Vietnam Maastricht, 18 th December 2002 Rhein Biotech will license its Hansenula polymorpha technology to the Vietnamese government (Ministry of Health) in a 28 million dollar contract, comprising the design, engineering and construction of two vaccine plants, in Hanoi and Dalat. The total contract is in the hand of a consortium of Rhein Biotech’s Korean subsidiary, GreenCross Vaccine Corp, and Samsung. This plant construction is part of a welfare program by the Korean government agency EDCF (Economic Development Cooperation Fund). Rhein Biotech will license its Hansenula polymorpha technology for the production of the recombinant Hepatitis B vaccine for the Vietnamese local market only. After the signing ceremony, the preparatory works will start. Completion of the project is planned in March 2005. end of ad-hoc-announcement (c)DGAP 18.12.2002 Issuer’s information/explanatory remarks concerning this ad-hoc-announcement: Berna Biotech AG (Swiss Exchange: BBIN) has acquired 92.2 percent of the Rhein Biotech share capital by means of a friendly take-over. Rhein Biotech is now a full member of the Berna Biotech group. For more information on Berna Biotech please visit: http://www.bernabiotech.com For further information Rhein Biotech N.V. Company Contact: Marcel Jacobs Communication Manager E: m.jacobs@rheinbiotech.com ——————————————————————————– WKN: 919544; ISIN: NL0000230324; Index: Listed: Geregelter Markt in Frankfurt; Freiverkehr in Berlin, Düsseldorf, Hamburg, Hannover, München und Stuttgart 180742 Dez 02